Trial Outcomes & Findings for The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia (NCT NCT01146457)

NCT ID: NCT01146457

Last Updated: 2017-04-25

Results Overview

Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.

Recruitment status

TERMINATED

Study phase

NA

Target enrollment

83 participants

Primary outcome timeframe

Participants were followed for the duration of delivery, an average of 7 hours

Results posted on

2017-04-25

Participant Flow

Participant milestones

Participant milestones
Measure
Placebo
Saline: Saline Control
Morphine 25
Morphine 25 micrograms: Active dosage
Morphine 50
Morphine 50 micrograms: Active dosage
Morphine 75
Morphine 75 micrograms: Active dosage
Morphine 100
Morphine 100 micrograms: Active dosage
Overall Study
STARTED
19
17
21
13
13
Overall Study
COMPLETED
19
17
20
13
13
Overall Study
NOT COMPLETED
0
0
1
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

The Optimal Dosage of Intrathecal Morphine for Peripartum Analgesia

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Placebo
n=19 Participants
Saline control
Morphine 25
n=17 Participants
Morphine 25 micrograms
Morphine 50
n=21 Participants
Morphine 50 micrograms
Hine 75
n=13 Participants
Morphine 75 micrograms
Morphine 100
n=13 Participants
Morphine 100 micrograms
Total
n=83 Participants
Total of all reporting groups
Age, Continuous
34.3 Years
STANDARD_DEVIATION 5.3 • n=5 Participants
31.5 Years
STANDARD_DEVIATION 5.3 • n=7 Participants
31.3 Years
STANDARD_DEVIATION 6.6 • n=5 Participants
32.5 Years
STANDARD_DEVIATION 5.5 • n=4 Participants
32.4 Years
STANDARD_DEVIATION 5.7 • n=21 Participants
32.3 Years
STANDARD_DEVIATION 5.7 • n=8 Participants
Sex: Female, Male
Female
19 Participants
n=5 Participants
17 Participants
n=7 Participants
21 Participants
n=5 Participants
13 Participants
n=4 Participants
13 Participants
n=21 Participants
83 Participants
n=8 Participants
Sex: Female, Male
Male
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
0 Participants
n=4 Participants
0 Participants
n=21 Participants
0 Participants
n=8 Participants

PRIMARY outcome

Timeframe: Participants were followed for the duration of delivery, an average of 7 hours

Rate of breakthrough pain is the number of episodes of breakthrough pain divided by the number of hours of labor. Time measured from placement of the neuraxial anesthetic, until delivery of the neonate. Because duration of labor is different for all patients, the rate of breakthrough pain per hour is used as the primary outcome.

Outcome measures

Outcome measures
Measure
Control
n=19 Participants
Saline Control
Morphine 25
n=17 Participants
Morphine 25 micrograms
Morphine 50
n=21 Participants
Morphine 50 micrograms
Morphine 75
n=13 Participants
Morphine 75 micrograms
Morphine 100
n=13 Participants
Morphine 100 micrograms
Rate of Breakthrough Pain
0.25 episodes of breakthrough pain per hour
Standard Deviation 0.29
0.28 episodes of breakthrough pain per hour
Standard Deviation 0.35
0.25 episodes of breakthrough pain per hour
Standard Deviation 0.25
0.23 episodes of breakthrough pain per hour
Standard Deviation 0.26
0.17 episodes of breakthrough pain per hour
Standard Deviation 0.21

Adverse Events

Placebo

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Morphine 25

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Morphine 50

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Morphine 75

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Morphine 100

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Philip Hess

BIDMC

Phone: 617-667-3353

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place